Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/63—Steroids; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers
  • A61K2800/522—Antioxidants; Radical scavengers

Definitions

• the present invention relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane for their antioxidant property. More particularly, the present invention relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as antioxidants in the cosmetic and food fields, and as antioxidant preservatives that can be used in particular in cosmetic and food products. , and pharmaceuticals.
• Oxidative stress is one of the biological consequences of the body's use of oxygen. It results in the formation of free radicals in the cells. Free radicals, if uncontrolled, can quickly react with molecules in their surroundings, giving rise to toxic compounds that can interfere with normal physiological processes. These substances can lead to cellular damage if the antiradical defenses are not sufficient. More and more studies show that reactive oxygen species play an important role in multiple biological processes and in particular in the development of multiple human pathologies, and in aging. The cumulative effects of these reactions can overwhelm normal mechanisms of cell repair.
• Preventing or treating skin aging, whether intrinsic or extrinsic, and the clinical signs described above, is to maintain or improve the appearance of the skin or scalp.
• Antioxidants are substances that neutralize free radicals or their actions. Thus, they help in protecting cells against free radical damage.
• antioxidant molecules are, for example, vitamins (A, E and C in particular), carotenoids (such as beta-carotene), polyphenols, and trace elements (such as selenium, copper and zinc).
• carotenoids such as beta-carotene
• trace elements such as selenium, copper and zinc.
• Antioxidants also have a beneficial effect when they are applied to the skin, they are indeed used in cosmetics.
• the use of antioxidants as preservatives in various types of oxidation-sensitive products is also known.
• antioxidants are sometimes inadequate or have insufficient action. It is known, for example, that tocopherol, which is a reference product in this field, is sensitive to light and requires particular preservation means.
• the present invention responds to this demand for potent antioxidant compounds since it relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as an antioxidant, which are potent antioxidants.
• the inventors have now shown the potent antioxidant role of at least one oxime derivative of 3,5-seco-4-nor-cholestane, and in particular the oxime of 3,5-seco-4-nor-cholestane.
• lipid peroxidation and also vis-à-vis substances likely to undergo thermo-or photo-induced oxidation reactions (such as proteins, sugars, pigments, vitamins, polymers).
• the present invention relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as an antioxidant.
• antioxidant refers to the ability of a compound to reduce the damage caused by free radicals: in the body, as an active ingredient in the cosmetic field and in the food field, and
• these compounds do not absorb in the UV / visible, they do not interfere with conventional solar products that absorb UV radiation and do not present a risk of chemical instability in this wavelength range; these compounds are in the form of crystalline powder and are very well preserved at room temperature, without any degradation for at least 12 months;
• a first aspect of the invention is the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane to protect the skin.
• the skin is especially the place of aggression of extrinsic and intrinsic toxic factors.
• Extrinsic factors include, for example, ultraviolet radiation, wind, low humidity, abrasives and strong surfactants.
• Intrinsic factors include chronological aging and biochemical changes in the skin.
• the compounds of the present invention are capable of providing effective protection against factors that cause the appearance of wrinkles and other histological changes associated with aging of the skin.
• the advantageous properties of the compounds of the invention also justify their use in a cream for protection against solar radiation, without any risk of disrupt the action of specially selected components for their UV absorption.
• the compounds of the invention are capable of capturing the activated form of oxygen by solar radiation. This activated form of oxygen, called singlet oxygen, is the reactive entity at the origin of cellular disturbances.
• Another aspect of the invention consists in the use of the compounds of the invention in cleansing and / or make-up removing products, as well as in products for protecting the skin and / or the hair against the side effects of UV radiation. .
• the antioxidant properties of at least one oxime derivative of 3,5-seco-4-nor-cholestane also recommend their use in the food field as a dietary supplement. It is therefore within the scope of the invention to use the compounds of the invention as antioxidants in the food field.
• the foods can be simple or compound foods, and may be presented in any of the usual known forms of human nutrition.
• preservative a compound which preserves a product of any physico-chemical alteration.
• the fatty substances and certain active substances used in the compositions tend to oxidize, even at ambient temperature, and that this oxidation makes them acquire new properties, especially olfactory properties. which are undesirable.
• soaps develop rancid, pungent and fruity odors after only a few weeks of storage in the air.
• these bad smells can be prevented or at least avoided during a much longer storage period, if one of the compounds of the invention is added to them.
• the addition salts with pharmaceutically acceptable acids may be for example salts formed with hydrochloric, hydrobromic, nitric, sulfuric, phosphoric acetic, formic, propionic, benzoic, maleic, fumaric, succinic or tartaric acids.
• one of the aspects of the invention is therefore to provide an antioxidant cosmetic composition comprising at least in a cosmetically acceptable medium an effective amount of at least one oxime derivative of 3,5-seco-4-nor-cholestane.
• the invention also relates to a cosmetic composition for combating chronobiological aging and / or photoinduced comprising in a cosmetically acceptable medium an effective amount of at least one oxime derivative of 3,5-seco-4-nor-cholestane.
• Extracts of plants such as Iridaceae or soybean extracts, which may then contain isoflavones or not;
• Nitrone DMPO (50 mM) is perfused at the beginning of the reperfusion at the inlet of the aorta so as to trap the free radicals produced in the coronary effluents. These effluents were collected by direct sampling into the coronary sinus at 3 minutes of reperfusion and then preserved in liquid nitrogen before analysis by RPE adducts formed on this nitrone. Spin trappinq on DMPO in coronary effluents
• the EPR signals characteristic of the DMPO-OH adduct are detected in the effluents at the third minute of reperfusion in the presence of DMPO (50 mM).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Mycology (AREA)
• Nutrition Science (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Birds (AREA)
• Biochemistry (AREA)
• Toxicology (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
• Medicinal Preparation (AREA)
• Steroid Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39167368

Family Applications (1)

Country Status (11)

Families Citing this family (4)

Family Cites Families (16)

• 2007
  • 2007-07-25 FR FR0705428A patent/FR2919182B1/fr not_active Expired - Fee Related
• 2008
  • 2008-07-24 MX MX2010000913A patent/MX2010000913A/es active IP Right Grant
  • 2008-07-24 NZ NZ582647A patent/NZ582647A/xx not_active IP Right Cessation
  • 2008-07-24 RU RU2010106609/15A patent/RU2476225C2/ru not_active IP Right Cessation
  • 2008-07-24 AU AU2008306755A patent/AU2008306755B2/en not_active Expired - Fee Related
  • 2008-07-24 WO PCT/FR2008/001102 patent/WO2009044011A2/fr active Application Filing
  • 2008-07-24 BR BRPI0814667-5A2A patent/BRPI0814667A2/pt not_active IP Right Cessation
  • 2008-07-24 EP EP08835696A patent/EP2173316A2/fr not_active Withdrawn
  • 2008-07-24 US US12/670,482 patent/US8338488B2/en not_active Expired - Fee Related
  • 2008-07-24 JP JP2010517451A patent/JP2010534228A/ja active Pending
  • 2008-07-24 CA CA2694148A patent/CA2694148A1/fr not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events